Targeted Nanoparticles for Imaging Incipient Pancreatic Ductal Adenocarcinoma

DSpace/Manakin Repository

Targeted Nanoparticles for Imaging Incipient Pancreatic Ductal Adenocarcinoma

Show simple item record Bardeesy, Nabeel Anbazhagan, Rajesh Berger, Justin Alencar, Herlen Kelly, Kimberly A. Gurumurthy, Sushma DePinho, Ronald A. Mahmood, Umar Weissleder, Ralph 2012-03-29T17:50:44Z 2008
dc.identifier.citation Kelly, Kimberly A., Nabeel Bardeesy, Rajesh Anbazhagan, Sushma Gurumurthy, Justin Berger, Herlen Alencar, Ronald A. DePinho, Umar Mahmood, and Ralph Weissleder. 2008. Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma . PLoS Medicine 5(4): e85. en_US
dc.identifier.issn 1549-1277 en_US
dc.description.abstract Background: Pancreatic ductal adenocarcinoma (PDAC) carries an extremely poor prognosis, typically presenting with metastasis at the time of diagnosis and exhibiting profound resistance to existing therapies. The development of molecular markers and imaging probes for incipient PDAC would enable earlier detection and guide the development of interventive therapies. Here we sought to identify novel molecular markers and to test their potential as targeted imaging agents. Methods and Findings: Here, a phage display approach was used in a mouse model of PDAC to screen for peptides that specifically bind to cell surface antigens on PDAC cells. These screens yielded a motif that distinguishes PDAC cells from normal pancreatic duct cells in vitro, which, upon proteomics analysis, identified plectin-1 as a novel biomarker of PDAC. To assess their utility for in vivo imaging, the plectin-1 targeted peptides (PTP) were conjugated to magnetofluorescent nanoparticles. In conjunction with intravital confocal microscopy and MRI, these nanoparticles enabled detection of small PDAC and precursor lesions in engineered mouse models. Conclusions: Our approach exploited a well-defined model of PDAC, enabling rapid identification and validation of PTP. The developed specific imaging probe, along with the discovery of plectin-1 as a novel biomarker, may have clinical utility in the diagnosis and management of PDAC in humans. en_US
dc.language.iso en_US en_US
dc.publisher Public Library of Science en_US
dc.relation.isversionof doi:10.1371/journal.pmed.0050085 en_US
dc.relation.hasversion en_US
dash.license LAA
dc.title Targeted Nanoparticles for Imaging Incipient Pancreatic Ductal Adenocarcinoma en_US
dc.type Journal Article en_US
dc.description.version Version of Record en_US
dc.relation.journal PLoS Medicine en_US Gurumurthy, Sushma 2012-03-29T17:50:44Z
dash.affiliation.other HMS^Medicine-Massachusetts General Hospital en_US
dash.affiliation.other HMS^Medicine-Brigham and Women's Hospital en_US
dash.affiliation.other HMS^Radiology-Massachusetts General Hospital en_US
dash.affiliation.other HMS^Systems Biology en_US

Files in this item

Files Size Format View
2292750.pdf 863.5Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record


Search DASH

Advanced Search